Brain-derived neurotrophic factor in neurodegenerative diseases

By C. Zuccato, E. Cattaneo. Nature Reviews Neurology, 2009

925 citations recorded by the source corpus.

Subfields: Cell Biology, Cellular and Molecular Neuroscience

View Paper: https://www.semanticscholar.org/paper/9238c4eadda071db1ad385c56417d258fc0cf45a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. Christopher A. Ross
2. Mark P. Mattson
3. D. Holtzman
4. Philip C. Wong
5. D. Krainc

In Cellular and Molecular Neuroscience

1. Undurti N. Das
2. Siresha Bathina
3. Mark P. Mattson
4. C. Zuccato
5. E. Cattaneo
6. M. Valenza
7. Wenzhen Duan
8. M. Chao

Citations in the corpus

• Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate (2016, background): “…question, since cognitive ability and synaptic plasticity are influenced by the levels of BDNF (Lu et al., 2013; Park and Poo, 2013; Vaynman et al., 2004) and BDNF signaling is reduced in many neurodegenerative and psychi- atric diseases (Autry and Monteggia, 2012; Zuccato and Cattaneo, 2009).”
• GDNF, NGF and BDNF as therapeutic options for neurodegeneration. (2013, background): “Whereas overexpression of wild type huntingtin protein in cell lines and in ‘Htt knock in’ transgenic mice, results in increased levels of BDNF, the presence ofmutant huntingtin produces a down regulation in BDNF production (Reilly, 2001; Canals et al., 2004; Zuccato & Cattaneo, 2009).”
• Gut microbiota are related to Parkinson's disease and clinical phenotype (2015, background): “Further possible mechanisms for microbiome–host interactions in PD could involve neurotoxins, neurotrophic factors, and neurotransmitters.(26,29,30,78,79) However, the relevance of the above-mentioned pathways with regard to PD remains unclear.”
• Brain-derived neurotrophic factor and its clinical implications (2015, background): “Decrease in the expression of BDNF is seen in many neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and bipolar disease [124–133], as detailed above.”
• BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity (2017, background): “Impairment of these mechanisms has been demonstrated in neurodegenerative diseases, such as Huntington’s and Alzheimer’s (Zuccato and Cattaneo 2009).”
• Amyloid Precursor Protein Processing and Alzheimer’s Disease (2011, background): “However, BDNF polymorphisms, which have been associated with other cognitive syndromes, have not been consistently associated with AD (Zuccato & Cattaneo 2009).”
• Molecular mechanisms and potential therapeutical targets in Huntington's disease. (2010, background): “Many laboratories have confirmed reduced BDNF levels in total brain or cortical samples from a large panel of HD animal models including R6/2, YAC, BAC-HD, N171-82Q and knock-in mice and HD rats (667, 668).”
• Neuroprotective role of SIRT1 in mammalian models of Huntington’s disease through activation of multiple SIRT1 targets (2011, positive): “Reduced BDNF concentration contributes to striatal dysfunction and degeneration, and an increase in BDNF concentration is neuro-protective in Huntington’s disease 25 .”